Furthermore, major classes of breast cancer therapeutics that target the hosts' cellular processes, such as the aromatase inhibitors, cannot be evaluated in intact breast cancer cells unless they have been manipulated to overexpress and, thus, depend on aromatase for their growth. Here, CYP19A1 is linked to breast carcinoma.